Allergic reaction to nanocolloid during lymphoscintigraphy for sentinel lymph node biopsy EditorÐWe read with interest the case report by Stefanutto and colleagues, 1 concerning an anaphylactic reaction to isosulphan blue dye during routine sentinel lymph node biopsy for breast surgery. We agree that anaesthetists must be aware of the potential serious risks of anaphylaxis in this group of patients. However, this is not a new ®nding; anaphylaxis to the blue dye has been well documented. 2 We would like to add a further potential area of concern that was highlighted recently in a patient, of what appears to be an allergic reaction to technetium 99m nanocolloid during lymphoscintigraphy.
The patient, a 31-yr-old male weighing 75 kg, was admitted to hospital after previous removal of a malignant melanoma (Breslow thickness 1 mm) from over his left scapula, for further wide local excision, lymphoscintigraphy, and sentinel node biopsy. He was taking no medications, and was without any signi®cant medical history. There was no past history of asthma or any atopic episodes. On the day before surgery, he underwent an intradermal injection of technetium 99m nanocolloid albumen. Within 10 min of injection of the colloid, the patient developed a widespread, non-itchy urticarial skin reaction. There was no associated wheeze, dif®culty breathing, or cardiovascular symptoms. Immediately, he was given chlorpheniramine 10 mg i.v., and the rash settled without further consequence over the next hour.
The subsequent general anaesthetic was carried out uneventfully. Induction of anaesthesia was facilitated with fentanyl 0.5 mg kg ±1 and propofol 2.5 mg kg ±1 . Anaesthesia was maintained using iso¯urane in oxygen and nitrous oxide with the patient breathing spontaneously. Chlorpheniramine 10 mg and hydrocortisone 100 mg were given intravenously at induction. During surgery, patent V blue dye 0.5 ml was injected intradermally without incident. Another general anaesthetic 5 weeks later for block dissection of axillary nodes was equally uneventful.
The use of sentinel lymph node biopsy in the staging of malignancies, particularly melanomas and breast cancers, has gained in popularity in recent years. The accuracy of injecting blue dye around the site of the primary malignancy can be increased using lymphoscintigraphy and intraoperative gamma probe detection after radiocolloid injection. The most commonly used radiopharmaceutical agent is technetium 99m nanocolloid, which requires standard radiation precautions to be taken when handling to protect personnel. We are unable to ®nd any reports of anaphylactoid type reactions to the radiocolloid in the literature. It could be argued that there is no evidence that the patient in this case had a true anaphylactic reaction. Further skin-prick testing was not carried out as the intradermal injection is a form of skin testing in itself. However, according to a classi®cation based on symptom severity, 3 our patient reacted with Grade 1 type cutaneous symptoms that can consist of generalized erythema, urticaria or angio-oedema. A similar reaction with a widespread blue rash occurred after injection of blue patent V dye during sentinel lymph node biopsy for breast carcinoma. 4 This was treated successfully with hydrocortisone and chlorpheniramine. We suggest that it is possible that there may be some cross reactivity with blue dye and it is worth noting even though the patient did not suffer any serious consequences. 
Anaphylactic reaction to isosulphan blue
EditorÐWe were interested to read the report from Dr Stefanutto and colleagues 1 concerning a patient who experienced an anaphylactic reaction to isosulphan blue during a sentinel lymph node biopsy (SNLB) associated with breast tumour surgery. We reported a similar case 2 of a lady undergoing breast tumour surgery who developed cardiovascular collapse about 30 min after peritumoural injection of blue dye for SNLB. She developed profound hypotension, associated with large red coloured trunkal wealds. As in Dr Stefanutto's patient, epinephrine, initially as i.v. increments of 0.1 mg followed by an infusion, was successful in reversing the hypotension and the patient recovered uneventfully. Serum tryptase and urinary methylhistamine levels were both signi®cantly raised, indicating an immune mechanism. Skin testing was positive to the blue dye at 1:10 and 1:5 concentrations.
Dr Stefanutto and colleagues emphasize the need to alert anaesthetic personnel to this potential reaction. We would also like to emphasize the delay between initial injection of blue dye and the onset of symptoms (about 25 min in our case). We would agree that full resuscitation equipment should be available whenever anaesthesia is carried out. We do not think, however, that the occurrence of these two cases should preclude the use of this technique in the day-case setting.
The patient we had been treating was part of the UK Axillary Lymphatic Mapping Against Nodal Axillary Clearance (ALMANAC) trial which aims to recruit 1200 patients, randomized to two arms. So far we have treated over 500 patients for SLNB using blue dye. Unlike Dr Stefanutto and colleagues, the UK ALMANAC trial does not use isosulphan blue but instead uses Patent Blue V dye manufactured by Laboratoire Guerbet (Aulnay-Sous-Bois, France). This drug is available world wide with the exception of the USA. It is the dye of choice for SNLB in the UK and throughout Europe. To date, ®ve other cases of anaphylactic reaction have been described with this dye.
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We have also noted two other cutaneous reactions that we believe are related to the use of Patent Blue V dye during SNLB. The ®rst reaction is the development of skin wealds, usually 
